Drug efflux transporters, in particular P-glycoprotein (Pgp), limit the success of chemotherapy. We previously found that synthetic doxorubicin conjugated with nitric oxide (NO)-releasing group overcomes resistance by inducing a NO-mediated inhibition of Pgp. Here we produced the first liposomal formulations of this nitrooxy-doxorubicin decorated with folic acid (FA), termed LNDF, in order to improve their active targeting against Pgp-expressing tumors. Folate was inserted onto liposomes surface using two different methods and the formulations were compared with respect to their technological features and in vitro behavior. By analyzing human and murine breast cancer cells with different expression of FA receptor (FAR) and Pgp, we demonstrated that LNDF are internalized in a FAR-dependent manner and achieve maximal anti-tumor efficacy against FAR-positive/Pgp-positive cells. Upon uptake of LNDF, nitrooxy-doxorubicin was delivered within nucleus, where it induced cell cycle arrest and DNA damages, and mitochondria, where it impaired the mitochondrial energy metabolism and triggered mitochondria-dependent apoptosis. LNDF reduced the growth of FAR-positive/Pgp-positive tumors and prevented tumor formation in mice, whereas doxorubicin and Caelyx® failed. LNDF cardiotoxicity was comparable to Caelyx®. The sensitivity to LNDF was maintained in tumors exposed to repeated cycles of the drug and in cells derived from the exposed tumors, excluding the onset of secondary resistance. By combining an innovative multitarget cargo drug, conceived to achieve high efficacy against Pgp-expressing cells, and appropriate strategies of liposome formulation and decoration, we produced a therapeutic tool that may represent a significant advancement in the treatment of FAR-positive/Pgp-positive tumors.

Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors

Gazzano, Elena;Rolando, Barbara
Co-first
;
Chegaev, Konstantin;Salaroglio, Iris C.;Kopecka, Joanna;Pedrini, Isabella;Sorge, Matteo;Buondonno, Ilaria;Stella, Barbara;Marengo, Alessandro;Brancaccio, Mara;Fruttero, Roberta;Gasco, Alberto;Arpicco, Silvia
Co-last
;
Riganti, Chiara
Co-last
2018

Abstract

Drug efflux transporters, in particular P-glycoprotein (Pgp), limit the success of chemotherapy. We previously found that synthetic doxorubicin conjugated with nitric oxide (NO)-releasing group overcomes resistance by inducing a NO-mediated inhibition of Pgp. Here we produced the first liposomal formulations of this nitrooxy-doxorubicin decorated with folic acid (FA), termed LNDF, in order to improve their active targeting against Pgp-expressing tumors. Folate was inserted onto liposomes surface using two different methods and the formulations were compared with respect to their technological features and in vitro behavior. By analyzing human and murine breast cancer cells with different expression of FA receptor (FAR) and Pgp, we demonstrated that LNDF are internalized in a FAR-dependent manner and achieve maximal anti-tumor efficacy against FAR-positive/Pgp-positive cells. Upon uptake of LNDF, nitrooxy-doxorubicin was delivered within nucleus, where it induced cell cycle arrest and DNA damages, and mitochondria, where it impaired the mitochondrial energy metabolism and triggered mitochondria-dependent apoptosis. LNDF reduced the growth of FAR-positive/Pgp-positive tumors and prevented tumor formation in mice, whereas doxorubicin and Caelyx® failed. LNDF cardiotoxicity was comparable to Caelyx®. The sensitivity to LNDF was maintained in tumors exposed to repeated cycles of the drug and in cells derived from the exposed tumors, excluding the onset of secondary resistance. By combining an innovative multitarget cargo drug, conceived to achieve high efficacy against Pgp-expressing cells, and appropriate strategies of liposome formulation and decoration, we produced a therapeutic tool that may represent a significant advancement in the treatment of FAR-positive/Pgp-positive tumors.
270
37
52
www.elsevier.com/locate/jconrel
Breast cancer; Chemoresistance; Doxorubicin; Folic acid; Liposomes; P-glycoprotein; 3003
Gazzano, Elena; Rolando, Barbara; Chegaev, Konstantin; Salaroglio, Iris C.; Kopecka, Joanna; Pedrini, Isabella; Saponara, Simona; Sorge, Matteo; Buondonno, Ilaria; Stella, Barbara; Marengo, Alessandro; Valoti, Massimo; Brancaccio, Mara; Fruttero, Roberta; Gasco, Alberto; Arpicco, Silvia; Riganti, Chiara
File in questo prodotto:
File Dimensione Formato  
Gazzano, J Control Rel manuscript and supporting, 2018.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 2.31 MB
Formato Adobe PDF
2.31 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
JCR-D-17-01292R1.pdf

Accesso riservato

Descrizione: Gazzano, J Controlled Release Opena Access, 2018
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 3.01 MB
Formato Adobe PDF
3.01 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
2018 Gazzano JCR.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 1.75 MB
Formato Adobe PDF
1.75 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Manuscript R1_JCR_per VQR.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 1.44 MB
Formato Adobe PDF
1.44 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1657290
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 48
social impact